Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exact Sciences Corporation    EXAS

EXACT SCIENCES CORPORATION

(EXAS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/22/2020 05/26/2020 05/27/2020 05/28/2020 05/29/2020 Date
83.59(c) 80.81(c) 82.11(c) 83.89(c) 85.88(c) Last
809 983 1 567 405 1 734 450 1 153 987 1 277 691 Volume
+0.50% -3.33% +1.61% +2.17% +2.37% Change
More quotes
Financials (USD)
Sales 2020 1 225 M - -
Net income 2020 -354 M - -
Net Debt 2020 380 M - -
P/E ratio 2020 -38,4x
Yield 2020 -
Sales 2021 1 827 M - -
Net income 2021 -186 M - -
Net Debt 2021 399 M - -
P/E ratio 2021 -78,9x
Yield 2021 -
Capitalization 12 860 M 12 860 M -
EV / Sales 2020 10,8x
EV / Sales 2021 7,26x
Nbr of Employees 4 110
Free-Float 98,7%
More Financials
Company
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect... 
More about the company
Surperformance© ratings of Exact Sciences Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on EXACT SCIENCES CORPORATION
05/06EXACT SCIENCES : 1Q Earnings Snapshot
AQ
05/06EXACT SCIENCES : Management's Discussion and Analysis of Financial Condition and..
AQ
04/24EXACT SCIENCES CORP : Change in Directors or Principal Officers (form 8-K)
AQ
03/15EXACT SCIENCES : Message from Chairman & CEO, Kevin Conroy
PU
03/11EXACT SCIENCES : Fight colorectal cancer reciveces grant from exact sciences to ..
PU
03/04EXACT SCIENCES : SEC Filing (424B7)
PU
02/21EXACT SCIENCES : Management's Discussion and Analysis of Financial Condition and..
AQ
02/19EXACT SCIENCES : SEC Filing - CT ORDER
PU
02/11EXACT SCIENCES : 4Q Earnings Snapshot
AQ
02/06EXACT SCIENCES CORPORATION : annual earnings release
01/31EXACT SCIENCES CORP : Amendments to Articles of Inc. or Bylaws; Change in Fiscal..
AQ
2019EXACT SCIENCES CORP : Other Events (form 8-K)
AQ
2019EXACT SCIENCES CORP : Completion of Acquisition or Disposition of Assets, Regula..
AQ
2019GENOMIC HEALTH : Exact Sciences Completes Combination with Genomic Health, Creat..
AQ
2019EXACT SCIENCES : Management's Discussion and Analysis of Financial Condition and..
AQ
More news
News in other languages on EXACT SCIENCES CORPORATION
05/06EXACT SCIENCES : 1Q Earnings Snapshot
05/06EXACT SCIENCES : Management's Discussion and Analysis of Financial Condition and..
04/24EXACT SCIENCES CORP : Change in Directors or Principal Officers (form 8-K)
03/15EXACT SCIENCES : Message from Chairman & CEO, Kevin Conroy
03/11EXACT SCIENCES : Fight colorectal cancer reciveces grant from exact sciences to ..
More news
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Average target price 97,73 $
Last Close Price 85,88 $
Spread / Highest target 33,9%
Spread / Average Target 13,8%
Spread / Lowest Target 0,14%
EPS Revisions
Managers
NameTitle
Kevin T. Conroy Chairman, President & Chief Executive Officer
Ana Hooker Senior Vice President-Operations
Jeffrey T. Elliott Chief Financial Officer
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sandra Statz SVP-Clinical & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
EXACT SCIENCES CORPORATION-7.14%12 860
GUARDANT HEALTH, INC.15.68%8 309
ADAPTIVE BIOTECHNOLOGIES CORPORATION30.08%4 938
IOVANCE BIOTHERAPEUTICS, INC.17.99%4 143
GENSCRIPT BIOTECH CORPORATION-3.95%3 907
SEEGENE INC--.--%2 539